Immutep Announces Publication of Abstracts at ESMO Congress 2023
16 Outubro 2023 - 9:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces the publication of abstracts with data from the TACTI-002
and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L
NSCLC) at the 2023 European Society for Medical Oncology (ESMO)
Congress.
TACTI-002 is a Phase II trial evaluating the
chemotherapy-free combination of eftilagimod alpha (“efti”) and
KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Rahway, NJ, USA)
anti-PD-1 therapy, in 1L NSCLC. The TACTI-002 abstract published by
ESMO, which contains data based on a cut-off date of 31 March 2023,
showed an excellent initial survival benefit across an all-comer
PD-L1 patient population in 1L NSCLC as well as for patients in
each PD-L1 Tumour Proportion Score (TPS) subgroup, including 38.8
months in TPS >50%, 23.4 months in TPS 1-49%, and 25.0 months in
TPS >1% (the OS result in TPS >1%, a key area of focus for
future development where efti has FDA Fast Track designation, was
already reported on May 17, 2023).
Notably, new updated data from TACTI-002,
including more mature Overall Survival (OS) results, will be
presented by Dr. Enric Carcereny, Catalan Institute of Oncology,
Badalona (ICO), during a Mini Oral session (#1312MO) at ESMO
Congress 2023 on Saturday, October 21, 2023, at 9:05 AM CEST.
INSIGHT-003 is an investigator-initiated Phase I
trial conducted by the Frankfurt Institute of Clinical Cancer
Research IKF evaluating efti in conjunction with KEYTRUDA® and
doublet chemotherapy in non-squamous 1L NSCLC patients. The data in
the INSIGHT-003 abstract, with a cut-off date of 18 April 2023,
showed a promising 67% overall response rate. Additionally, a
Trials in Progress (TiP) abstract on the EFTISARC-NEO trial
evaluating efti in combination with radiotherapy and KEYTRUDA®
titled has been published.
Abstracts are available on
the ESMO website, and the mini oral presentation &
posters will be available on Immutep’s website following their
presentation.
Presentation
Details:Title: Combining the
antigen-presenting cell activator eftilagimod alpha (soluble LAG-3)
and pembrolizumab: overall survival data from the 1st line
non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase
II)
- Presenter: Dr. Enric Carcereny,
Catalan Institute of Oncology, Badalona (ICO)
- Date and Time: Saturday, October
21, 2023; 9:10 AM CEST
- Mini Oral session – NSCLC,
metastatic
- Presentation # 1312MO
Title: INSIGHT-003 evaluating feasibility of
eftilagimod alpha (soluble LAG-3) combined with 1st line
chemo-immunotherapy in metastatic non-small cell lung cancer
(NSCLC) adenocarcinomas
- Speaker: Dr. Akin Atmaca,
Krankenhaus Nordwest (IKF)
- Date: Monday, October 23, 2023
- Poster presentation, # 1042P
Title: Pembrolizumab in combination with
eftilagimod alpha and radiotherapy in neoadjuvant treatment of
patients with soft tissue sarcomas – EFTISARC-NEO trial
- Speaker: Dr. Katarzyna Kozak, Maria
Skłodowska-Curie National Research Institute of Oncology
- Date: Monday, October 23, 2023
- Poster presentation, # 1987TiP
Conference Call and
Webcast:Immutep will host a conference
call and webcast to discuss the clinical data presented at ESMO
2023 and provide an overview on future clinical development plans
for efti in 1st line non-small cell lung cancer. The event will
feature Immutep CEO Marc Voigt, CSO Dr Frederic Triebel, CMO Dr
Florian Vogl, and Christian Mueller, Senior Vice President
Strategic Development. An open question & answer session with
all presenters will conclude the event. A replay of the webcast
will be available under the Events section of Immutep’s
website.
- Date/Time: Monday, October 23rd, at
8AM AEDT (Sunday, October 22nd, at 5PM ET)
- Register: Link to register
here.
- Questions: Investors are invited to
submit questions in advance via immutep@citadelmagnus.com.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About Eftilagimod Alpha
(Efti)Efti is Immutep’s proprietary soluble LAG-3 protein
and MHC Class II agonist that stimulates both innate and adaptive
immunity for the treatment of cancer. As a first-in-class antigen
presenting cell (APC) activator, efti binds to MHC (major
histocompatibility complex) Class II molecules on APC leading to
activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper
T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like IFN-ƴ
and CXCL10 that further boost the immune system’s ability to fight
cancer.
Efti is under evaluation for a variety of solid
tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its
favourable safety profile enables various combinations, including
with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has
received Fast Track Designation in 1st line HNSCC and in 1st line
NSCLC from the United States Food and Drug Administration
(FDA).
About ImmutepImmutep is a
clinical-stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S. Investors/Media:Chris
Basta, VP, Investor Relations and Corporate Communications+1 (631)
318 4000; chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024